pirfenidone has been researched along with Cirrhosis in 115 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (4.35) | 18.2507 |
| 2000's | 15 (13.04) | 29.6817 |
| 2010's | 54 (46.96) | 24.3611 |
| 2020's | 41 (35.65) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, W; Li, Q; Ma, Z; Pan, Y; Shen, Z; Wang, Z; Yang, Y; Zhang, X; Zhao, Y | 1 |
| Bailie, M; Campbell, PL; Dexheimer, T; Fox, DA; Haak, AJ; Hutchings, KM; Kahl, DJ; Khanna, D; Larsen, SD; Leipprandt, JR; Lisabeth, EM; Neubig, RR; Sun, D; Tsou, PS; Wen, B | 1 |
| Aimo, A; Bayes-Genis, A; Emdin, M; Lupón, J; Panichella, G; Spitaleri, G | 1 |
| Armendariz-Borunda, J; Galicia-Moreno, M; Lucano-Landeros, S; Miranda-Roblero, HO; Monroy-Ramirez, HC; Sandoval-Rodriguez, A; Santos, A; Silva-Gomez, JA | 1 |
| C Jacob, HK; Dawra, RK; Dudeja, V; Edwards, DB; Ferrantella, A; George, J; Giri, B; Gomez Aguilar, B; Iyer, S; Jain, T; Maynard, CL; Palathingal Bava, E; Sahay, P; Saluja, AK; Sethi, V; Sharma, P; Tarique, M; Vaish, U | 1 |
| Al-Karmalawy, AA; Antar, SA; El-Azab, MF; Hazem, RM; Nafea, YK; Saleh, MA | 1 |
| Chai, D; Guo, Z; Han, L; Huang, N; Li, H; Li, J; Li, L; Lv, Y; Wang, G; Xu, D; Zheng, J; Zheng, W; Zhou, X | 1 |
| Aimo, A; Bayes-Genis, A; Burchielli, S; Emdin, M; Galvez-Monton, C; Iborra-Egea, O; Martini, N; Panichella, G; Passino, C | 1 |
| Fujiwara, Y; Fukunaga, S; Higashimori, A; Hirano, S; Hosomi, S; Kamata, N; Nadatani, Y; Nagami, Y; Ominami, M; Otani, K; Taira, K; Tanaka, F; Tanigawa, T; Watanabe, T | 1 |
| Dawra, RK; Dudeja, V; George, J; Giri, B; Iyer, S; Jain, T; Palathingal Bava, E; Sahay, P; Saluja, AK; Sharma, P; Tarique, M; Vaish, U | 1 |
| Hang, W; Li, N; Shu, H; Zhou, N | 1 |
| Cunnington, C; Dodd, S; Lewis, GA; McDonagh, T; Miller, CA; Rosala-Hallas, A; Schelbert, EB; Williams, SG | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Batiha, GE; Faidah, H; Saad, HM; Simal-Gandara, J | 1 |
| Bo, C; Jia, Q; Li, M; Tang, Q; Xing, C; Zhang, Z | 1 |
| Fu, Y; Guo, Y; Liao, B; Liu, L; Ma, H; Ma, L; Qian, H; Qin, C; Shen, J; Shi, J | 1 |
| Chen, C; Chen, X; Cheng, J; Ji, J; Lu, Y; Zhang, F | 1 |
| Al-Karmalawy, AA; Antar, SA; Saleh, MA | 1 |
| Caplazi, P; Ding, N; Gierke, S; LaCanna, R; Ma, HY; Moffat, J; N'Diaye, EN; Uttarwar, S; Vander Heiden, JA; Wolters, PJ; Xi, Y | 1 |
| Huang, N; Jiang, QG; Lin, JQ; Yan, LY; Yang, WZ; Zheng, H | 1 |
| Bues, B; DeGrave, AN; Doan, TP; Lutz, S; Meyer, FEU; Santos, GL | 1 |
| Cunnington, C; Dodd, S; Lewis, GA; McDonagh, T; Miller, CA; Rosala-Hallas, A; Schelbert, EB; Soltani, F; Williams, SG | 1 |
| Kolb, M; Lehmann, M | 1 |
| Gao, H; Gong, B; Gong, T; Huang, Y; Luo, S; Zhang, L; Zhang, R; Zhao, T | 1 |
| Aimo, A; Aquaro, GD; Barison, A; Burchielli, S; Emdin, M; Masotti, S; Modena, M; Musetti, V; Passino, C; Pucci, A; Terlizzi, D | 1 |
| Chen, Z; Wu, C; Yang, Y; Yu, M; Zeng, B; Zhu, X | 1 |
| Leung, KP; Wells, AR | 1 |
| Adamo, L; Aimo, A; Barison, A; Bartolucci, G; Biagini, S; Cerbai, E; Emdin, M; Lo Surdo, G; Passino, C | 1 |
| Chen, Q; Cun, Q; Tao, Y; Yang, W; Yang, X; Zhang, Y; Zhao, C; Zhong, H; Zhu, Y | 1 |
| Cheng, YL; Li, LX; Shi, JX | 1 |
| Barrett, VJ; Brockbank, S; Cruwys, S; Dabbagh, RQ; Genovese, F; Good, RB; Jessen, H; Karsdal, MA; Leeming, DJ; Nanthakumar, CB; Rønnow, SR; Sand, JMB; Sorensen, GL | 1 |
| AlQudah, M; Czubryt, MP; Hale, TM | 1 |
| Agarwala, P; DeLeon, J; Glass, AD; Glass, DS; Grossfeld, D; Kasselman, LJ; Reiss, AB; Renna, HA; Spiegler, P | 1 |
| Armendáriz-Borunda, J; Gutiérrez-Cuevas, J; Monroy-Ramírez, HC; Sandoval-Rodríguez, A; Santos-García, A; Vazquez-Del Mercado, M | 1 |
| Bonella, F; Grunewald, J; Miedema, JR; Spagnolo, P | 1 |
| Beloki, L; Carruthers, A; Chahboub, A; Clarke, D; Dunmore, R; Güler-Gane, G; Koch, S; Kuziora, M; Lewis, A; Liarte Marin, E; May, R; Miranda, E; Murray, L; Overed-Sayer, C; Parfrey, H; Rassl, D | 1 |
| Latella, G; Viscido, A | 1 |
| Dygai, A; Ermakova, N; Krupin, V; Kubatiev, A; Morozov, S; Nebolsin, V; Novikov, F; Pakhomova, A; Pan, E; Pershina, O; Sandrikina, L; Skurikhin, E; Widera, D; Zhukova, M | 1 |
| Chen, D; Liu, Y; Sun, Y; Zhang, J; Zhang, X; Zhang, Z; Zhu, D | 1 |
| Guan, H; Jiao, M; Kong, N; Li, Y; Liu, X; Tian, R; Wang, K; Wei, Q; Yang, P | 1 |
| Allard, B; Batteux, F; Blanco, P; Chizzolini, C; Constans, J; Contin-Bordes, C; Duffau, P; Forcade, E; Groppi, A; Henrot, P; Izotte, J; Jeljeli, M; Jolivel, V; Laurent, P; Lazaro, E; Leleu, D; Levionnois, E; Manicki, P; Pradeu, T; Richez, C; Schaeverbeke, T; Seneschal, J; Truchetet, ME | 1 |
| Cao, ZJ; Dai, HP; Han, ZF; Li, BC; Li, ZG; Liu, Y; Pang, JL; Qi, XM; Song, MY; Wang, C; Wang, J; Yang, PR; Zhang, XR; Zhang, Z | 1 |
| Chen, M; Chen, Y; Fang, M; Hang, QQ; Qian, X; Ying, H | 1 |
| Chan, DD; Cole, BJ; Li, J; Luo, W; Plaas, A; Predescu, DN | 1 |
| Mora, M; Zanotti, S | 1 |
| Ghazi-Khansari, M; Heidari, MR; Iranpour, M; Mandegary, A; Pourgholamhossein, F; Pourgholi, L; Pournamdari, M; Poursalehi, HR; Rasooli, R; Samareh-Fekri, M | 1 |
| Chen, ZF; Chi, P; Ke, XJ; Sun, YW; Wu, XJ; Zhang, YY | 1 |
| Hall, CL; Leung, KP; Wells, AR | 1 |
| Epstein Shochet, G; Shitrit, D; Wollin, L | 1 |
| Dai, M; Hu, C; Hu, Y; Li, H; Li, Q; Li, Y; Liu, S; Long, Y; Mao, Z; Pan, P; Song, C; Su, X; Tan, H; Wu, D; Zhang, L | 1 |
| Asmani, M; Chen, Z; Hinz, B; Hsia, I; Li, Y; Velumani, S; Wawrzyniak, N; Zhao, R | 1 |
| Joensuu, E; Koli, K; Li, C; Myllärniemi, M; Rezov, V; Rönty, M; Vartiainen, V; Yin, M | 1 |
| Grabow, N; Guthoff, RF; Reske, T; Schmidt, W; Schmitz, KP; Siewert, S; Stahnke, T; Wree, A | 1 |
| Isaka, Y | 1 |
| Ammar, R; Huang, X; Jarai, G; Li, L; Ravi, K; Thompson, J; Wang, Y; Zhang, Y | 1 |
| Pata, YS; Türkmen, E | 1 |
| Bondue, B; Castiaux, A; Doumont, G; Egrise, D; Goldman, S; Huaux, F; Lacroix, S; Mathey, C; Sherer, F; Van Simaeys, G | 1 |
| Baynes, R; Khattab, A; Mowat, F; Oh, A; Salmon, B; Westermeyer, HD; Yeatts, J | 1 |
| Heukels, P; Kool, M; Moor, CC; von der Thüsen, JH; Wijsenbeek, MS | 1 |
| Ahmed, FZ; Bedson, E; Clayton, D; Cooper, A; Cunnington, C; Dodd, S; Eccleson, H; Jimenez, BD; Lewis, GA; McDonagh, T; Miller, CA; Naish, JH; Neubauer, S; Russell, S; Schelbert, EB; Viswesvaraiah, R; Williams, SG; Williamson, PR | 1 |
| Akduman, B; Bolat, MS; Bulut, E; Cinar, O; Demirkiran, ED; Erdem, S; Girgin, R; Kaymaz, E; Mungan, NA | 1 |
| He, JM; Qiu, ZZ; Yu, ZH; Zhang, HX; Zhang, ZW; Zhou, H | 1 |
| Ihle, F; Neurohr, C; von Wulffen, W | 1 |
| Chen, J; Li, H; Wang, Y; Wu, Y; Zhao, S | 1 |
| Chen, JF; Chen, PS; Liu, BC; Liu, H; Lv, LL; Ni, HF; Tang, RN; Zhang, AH; Zhang, MH | 1 |
| Endo, K; Iwai, N; Ji, X; Kito, N; Li, J; Ma, X; Naito, Y; Weng, H; Yanagawa, N; Yu, Y | 1 |
| Tampe, D; Zeisberg, M | 1 |
| Aguirre-Jauregui, O; Armendáriz-Borunda, J; Lucano-Landeros, MS; Orozco-Perez, J; Salazar-Montes, AM; Sobrevilla-Navarro, AA | 1 |
| Leask, A | 1 |
| Duan, LJ; Gu, X; Huang, T; Kong, XJ; Qi, J; Qian, XQ; Xu, D | 1 |
| Akazawa, H; Ishizu, T; Komuro, I; Lee, JK; Miwa, K; Naito, AT; Oka, T; Sakata, Y; Wang, Q; Yamagami, K | 1 |
| Fu, ST; He, Y; Jin, SF; Liu, ZL; Ma, HL; Zhang, CP | 1 |
| Armendariz-Borunda, J; Lopez-de la Mora, DA; Lucano-Landeros, S; Macias-Barragan, J; Montoya-Buelna, M; Sanchez-Enriquez, S; Sanchez-Roque, C | 1 |
| Bragato, C; Maggi, L; Mantegazza, R; Mora, M; Morandi, L; Zanotti, S; Zucchella, A | 1 |
| Bollmann, G; Cosín-Roger, J; Fagagnini, S; Hausmann, M; Hünerwadel, A; Lang, S; Lutz, C; Mamie, C; Meier, R; Rogler, G; Tchouboukov, A; Weber, A; Weber, FE | 1 |
| Jung, KI; Park, CK | 1 |
| Dahlerup, JF; Dige, A; Kadir, SI; Kelsen, J; Kok Jensen, S; Wenzel Kragstrup, T | 1 |
| Gu, C; Li, Z; Liu, X; Nie, Y; Wang, B; Wang, Q; Wen, J | 1 |
| Ali, SA; Batra, SK; Chakraborty, S; Das, B; Dash, P; Jain, S; Mohanty, AK; Panda, SK; Senapati, S; Suklabaidya, S; Swaminathan, S | 1 |
| Chen, G; Deng, Y; Gu, G; Guo, K; Hu, Q; Li, G; Li, J; Li, R; Li, Y; Ren, J; Wang, G; Wu, L | 1 |
| Gao, Y; Han, R; He, J; Kang, L; Li, C; Li, Y; Tian, J; Wang, J | 1 |
| Guthoff, RF; Hovakimyan, M; Kowtharapu, BS; Schmitz, KP; Stachs, O; Stahnke, T; Wree, A; Wurm, J | 1 |
| Ahn, YB; Ko, SH; Lee, E; Ryu, GR; Song, KH | 1 |
| Boor, P; Floege, J; Goldschmeding, R; Klinkhammer, BM | 1 |
| Hu, GY; Li, BX; Ning, WB; Peng, ZZ; Shen, H; Tang, YT; Tao, LJ; Wang, L; Wang, NS; Xie, YY | 1 |
| Chikanishi, T; Fujimori, A; Itoh, H; Iwatsuki, Y; Nakajima, H; Okada, M; Takakuta, K; Tanokura, A; Yamamoto, M | 1 |
| Cho, ME; Kopp, JB | 1 |
| Ding, C; Marcus, GM; Nguyen, DT; Olgin, JE; Wilson, E | 1 |
| Hayden, T | 1 |
| Cho, M; Donohue, M; Dunn, SR; Falkner, B; Fervenza, FC; Francos, B; Ix, JH; Kopp, JB; Mathew, AV; McGowan, TA; Pflueger, A; Ramachandrarao, S; Sharma, K; Sharma, S; Xu, R | 1 |
| Hanatani, A; Iwao, H; Izumi, Y; Muro, T; Nakamura, Y; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M | 1 |
| Bai, J; Hou, Q; Hu, G; Lao, Z; Li, Z; Lou, Q; Luo, R; Meng, X; Tao, L; Xuan, L | 1 |
| Choi, C; Choi, K; Im, M; Kook, KH; Lee, K; Ryu, SW | 1 |
| Itoh, H; Sanagi, M; Tahara, A; Takakura, K; Tomura, Y | 1 |
| Chuang, PY; He, JC; Menon, MC | 1 |
| Bajwah, S; Higginson, IJ; Koffman, J; Patel, AS; Peacock, JL; Riley, J; Ross, JR; Wells, AU | 1 |
| Cui, L; Eguchi, D; Fujiwara, K; Ikenaga, N; Kozono, S; Mizumoto, K; Ohuchida, K; Tanaka, M | 1 |
| Buckpitt, AR; Giri, SN; Lango, J; Margolin, SB; Morin, D; Wang, Q; Xie, Y | 1 |
| Al-Bayati, MA; Giri, SN; Margolin, SB; Mohr, FC; Xie, Y | 1 |
| Dosanjh, A; Ikonen, T; Morris, RE; Wan, B | 1 |
| Bao, L; Cho, IH; Hyun, BH; Kim, YJ; Lee, CH; Margolin, SB; Park, HS; Park, YH | 1 |
| Lasky, J | 1 |
| Bicknell, GR; Brook, NR; Nicholson, ML; Waller, JR | 1 |
| Fukuda, T; Kurasawa, K | 1 |
| Hoey, AJ; Irwin, NG; Van Erp, C | 1 |
| Farkas, GA; Gosselin, LE; Personius, K; Williams, JE | 1 |
| Altemus, RM; Augustine, E; Camphausen, KA; Gerber, L; Mitchell, JB; Simone, NL; Smith, S; Soule, BP | 1 |
| Shihab, FS | 1 |
| Furutani, S; Komemushi, S; Margolin, S; Ota, K; Suga, H; Teraoka, S; Yamauchi, S | 1 |
| Azuma, N; Hasegawa, S; Margolin, SB; Nakazawa, R; Narita, M; Ohbayashi, S; Ota, K; Taniyama, M; Teraoka, S; Yamauchi, S | 1 |
| Fukagawa, M; Hata, S; Iwasaki, Y; Kuroda, T; Kurokawa, K; Margolin, SB; Nemoto, M; Shimizu, F; Shimizu, T; Shirai, K; Yamauchi, S | 1 |
| Fukagawa, M; Hata, S; Kuroda, T; Kurokawa, K; Margolin, SB; Shimizu, T | 1 |
| Fukagawa, M; Kurokawa, K; Noda, M; Shimizu, T | 1 |
| Brown, L; Dallemagne, C; Endre, Z; Margolin, S; Miric, G; Taylor, SM | 1 |
| Cohen, EP; Fish, BL; Moulder, JE; Raife, TJ; Regner, KR | 1 |
| Brown, L; Fenning, A; Margolin, SB; Mirkovic, S; Seymour, AM; Strachan, A; Taylor, SM | 1 |
19 review(s) available for pirfenidone and Cirrhosis
| Article | Year |
|---|---|
Pirfenidone as a novel cardiac protective treatment.
Topics: Animals; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Myocytes, Cardiac; Pyridones | 2022 |
Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals.
Topics: Acute Lung Injury; COVID-19 Drug Treatment; Fibrosis; Goals; Humans; Pulmonary Fibrosis; Respiratory Distress Syndrome; SARS-CoV-2 | 2022 |
Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2.
Topics: Angiotensins; Anti-Inflammatory Agents; Antioxidants; Collagen Type I; COVID-19 Drug Treatment; Fibrosis; Humans; Inflammation; Interleukin-1beta; Platelet-Derived Growth Factor; Pyridones; SARS-CoV-2; Transforming Growth Factor beta1; Transforming Growth Factors; Tumor Necrosis Factor-alpha | 2022 |
Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence.
Topics: Animals; Cardiotonic Agents; Fibrosis; Heart; Humans; Myocardium; Pyridones | 2020 |
[Progress in randomized clinical trials of antifibrotic drug nintedanib and pirfenidone].
Topics: Fibrosis; Humans; Indoles; Pyridones; Randomized Controlled Trials as Topic | 2020 |
Targeting the renin-angiotensin-aldosterone system in fibrosis.
Topics: Amides; Angiotensins; Animals; Benzimidazoles; Biphenyl Compounds; Extracellular Matrix; Extracellular Matrix Proteins; Fibroblasts; Fibrosis; Fumarates; Gene Expression Regulation; Humans; Kidney; Liver; Molecular Targeted Therapy; Myocardium; Pyridones; Renin-Angiotensin System; Signal Transduction; Skin; Tetrazoles; Transforming Growth Factor beta | 2020 |
Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches.
Topics: Aged; Aged, 80 and over; Biomarkers; Disease Progression; Female; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Lung Transplantation; Male; Middle Aged; Prognosis; Pyridones; Telomere | 2020 |
Looking into the future of sarcoidosis: what is next for treatment?
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Biological Products; Cytokines; Dendritic Cells; Fibrosis; Glucocorticoids; Humans; Immunosuppressive Agents; Inflammasomes; Macrophages; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Sarcoidosis; T-Lymphocytes | 2020 |
Targeting TGF-β Signaling in Kidney Fibrosis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Fibrosis; Humans; Kidney; Kidney Diseases; Molecular Targeted Therapy; Pyridones; Signal Transduction; Transforming Growth Factor beta | 2018 |
Inflammation and immunity in IPF pathogenesis and treatment.
Topics: Adaptive Immunity; Anti-Inflammatory Agents; Clinical Trials as Topic; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Immunity, Innate; Indoles; Inflammation; Protein Kinase Inhibitors; Pyridones | 2019 |
Potential approaches to reverse or repair renal fibrosis.
Topics: Anti-Inflammatory Agents; Bone Morphogenetic Protein 7; Connective Tissue Growth Factor; Disease Progression; Endothelin-1; Epigenesis, Genetic; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Microcirculation; Phosphodiesterase Inhibitors; Pyridones; Transforming Growth Factor beta | 2014 |
Getting to the heart of the matter: new insights into cardiac fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Atrophy; Cicatrix; Connective Tissue Growth Factor; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Humans; Hypoxia; Models, Cardiovascular; Molecular Targeted Therapy; Myocardium; Myofibroblasts; Platelet-Derived Growth Factor; Pyridones; Rats; Signal Transduction; Transforming Growth Factor beta | 2015 |
Role and New Insights of Pirfenidone in Fibrotic Diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Eye; Fibrosis; Humans; Kidney; Liver Cirrhosis; Myocardium; Pulmonary Fibrosis; Pyridones | 2015 |
Treatment of Renal Fibrosis-Turning Challenges into Opportunities.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Biomarkers; Connective Tissue Growth Factor; Elasticity Imaging Techniques; Endpoint Determination; Extracellular Matrix; Fibrosis; Galectin 3; Humans; Kidney; Magnetic Resonance Imaging; Polysaccharides; Pyridones; Renal Insufficiency, Chronic; Transforming Growth Factor beta | 2017 |
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Drug Evaluation; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones | 2010 |
Molecular targets for treatment of kidney fibrosis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; beta Catenin; Carrier Proteins; Connective Tissue Growth Factor; Fibrosis; Gene Expression Regulation; Humans; Kidney; Molecular Targeted Therapy; NF-kappa B; ortho-Aminobenzoates; Protective Agents; Protein Serine-Threonine Kinases; Pyridones; Signal Transduction; Transforming Growth Factor beta | 2013 |
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Cough; Dyspnea; Exercise Test; Fibrosis; Glucocorticoids; Heroin; Humans; Immunologic Factors; Lung; Lung Diseases, Interstitial; Narcotics; Oxygen Inhalation Therapy; Piperazines; Prednisolone; Purines; Pyridones; Quality of Life; Sildenafil Citrate; Sulfones; Thalidomide; Tubulin Modulators | 2013 |
Pirfenidone.
Topics: Animals; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fibrosis; Humans; Pyridones; Structure-Activity Relationship | 2004 |
[Interstitial pneumonia].
Topics: Apoptosis; Chemokines; Cytokines; Fibrosis; Humans; Immunosuppressive Agents; Inflammation; Interferon-gamma; Lung Diseases, Interstitial; Lung Transplantation; Macrophages; Pyridones; Respiratory Function Tests; Th1 Cells; Th2 Cells; Tomography, X-Ray Computed | 2005 |
7 trial(s) available for pirfenidone and Cirrhosis
| Article | Year |
|---|---|
Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone.
Topics: Fibrosis; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Pyridones; Stroke Volume; Ventricular Function, Left | 2022 |
Treatment Adherence in a Randomized Controlled Trial of Pirfenidone in HFpEF: Determinants and Impact on Efficacy.
Topics: Fibrosis; Heart Failure; Humans; Stroke Volume; Treatment Adherence and Compliance; Ventricular Function, Left | 2023 |
Effects of pirfenidone on scar size and ventricular remodeling after myocardial infarction: a preclinical study.
Topics: Animals; Cicatrix; Fibrosis; Humans; Male; Myocardial Infarction; Rats; Rats, Wistar; Ventricular Remodeling | 2023 |
Safety and efficacy of topically applied 0.5% and 1% pirfenidone in a canine model of subconjunctival fibrosis.
Topics: Administration, Topical; Animals; Aqueous Humor; Conjunctival Diseases; Disease Models, Animal; Dogs; Drug Implants; Female; Fibrosis; Pyridones; Random Allocation | 2019 |
Pirfenidone for diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Creatinine; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrosis; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Pyridones; Treatment Outcome | 2011 |
Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study.
Topics: Administration, Oral; Antineoplastic Agents; Cohort Studies; Fibrosis; Humans; Male; Middle Aged; Pain Measurement; Pilot Projects; Prospective Studies; Pyridones; Radiation Injuries; Radiotherapy; Treatment Outcome | 2007 |
Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Fibrosis; Humans; Male; Middle Aged; Pyridones; Renal Dialysis | 1997 |
89 other study(ies) available for pirfenidone and Cirrhosis
| Article | Year |
|---|---|
Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents.
Topics: Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Fibrosis; Humans; Models, Molecular; Molecular Structure; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridones; Signal Transduction; Structure-Activity Relationship | 2014 |
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.
Topics: Animals; Carboxylic Acids; Connective Tissue Growth Factor; Enzyme Inhibitors; Female; Fibrosis; Mice, Inbred C57BL; Microsomes, Liver; Molecular Structure; Oxadiazoles; rho GTP-Binding Proteins; Scleroderma, Systemic; Serum Response Factor; Signal Transduction; Skin; Structure-Activity Relationship; Trans-Activators; Transcription, Genetic | 2019 |
Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio.
Topics: Animals; Anti-Inflammatory Agents; Carcinogenesis; Carcinoma, Hepatocellular; Fibrosis; Inflammation; Liver Neoplasms; Male; NF-kappa B; NF-kappa B p50 Subunit; Phosphorylation; PPAR gamma; Pyridones; Rats; Rats, Inbred F344; Signal Transduction; Transcription Factor RelA; Transforming Growth Factor beta1 | 2021 |
Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models.
Topics: Acinar Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Cytokines; Disease Models, Animal; Fibrosis; Interleukin-10; Macrophages; Mice; Pancreas; Pancreatitis; Paracrine Communication; Pyridones; Signal Transduction | 2022 |
Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Doxorubicin; Female; Fibrosis; Kidney Diseases; Mice; Pyridones; Vitamin D; Vitamins | 2022 |
The Anti-fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β.
Topics: Animals; Carcinoma, Renal Cell; Epithelial-Mesenchymal Transition; Female; Fibrosis; Humans; Kidney Neoplasms; Male; Mice; Pyridones; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment | 2022 |
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis.
Topics: Animals; Computational Biology; Fibrosis; Myocardial Infarction; Myocardium; Pyridones; Swine; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Pirfenidone prevents esophageal stricture by inhibiting nucleotide binding oligomerization domain like receptor protein 3 inflammasome activation.
Topics: Animals; Carrier Proteins; Caspase 1; Constriction, Pathologic; Esophageal Stenosis; Fibrosis; Humans; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin Domain-Containing 3 Protein; Nucleotides; Pyridones; Rats; Ulcer | 2022 |
Pirfenidone ameliorates chronic pancreatitis in mouse models through immune and cytokine modulation.
Topics: Acute Disease; Animals; Arginine; Ceruletide; Collagen; Cytokines; Disease Models, Animal; Fibrosis; Humans; Mice; Pancreatitis, Chronic; Pyridones | 2022 |
Pirfenidone alleviates cardiac fibrosis induced by pressure overload via inhibiting TGF-β1/Smad3 signalling pathway.
Topics: Animals; Fibrosis; Heart Failure; Male; Mice; Mice, Inbred C57BL; Myocardium; Pyridones; Smad3 Protein; Transforming Growth Factor beta1 | 2022 |
Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2/STAT3 signaling pathways.
Topics: Animals; Fibrosis; Hydroxyproline; Interleukin-18; Janus Kinase 2; Macrophages; Pneumonia; Pulmonary Fibrosis; Pyridones; Rats; RNA, Messenger; Signal Transduction; Silicosis; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vimentin | 2022 |
Alleviation of cardiac fibrosis using acellular peritoneal matrix-loaded pirfenidone nanodroplets after myocardial infarction in rats.
Topics: Animals; Collagen; Fibrosis; Myocardial Infarction; Myocardium; Pyridones; Rats | 2022 |
Pirfenidone-loaded hyaluronic acid methacryloyl hydrogel for preventing epidural adhesions after laminectomy.
Topics: Animals; Epidural Space; Fibrosis; Hyaluronic Acid; Hydrogels; Laminectomy; Rats; Tissue Adhesions | 2023 |
Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone.
Topics: Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Myofibroblasts; Trans-Activators; Transcription Factors | 2023 |
Effect and mechanism of pirfenidone combined with 2-methoxy-estradiol perfusion through portal vein on hepatic artery hypoxia-induced hepatic fibrosis.
Topics: 2-Methoxyestradiol; Animals; Collagen; Fibrosis; Hepatic Artery; Hypoxia; Liver Cirrhosis; Matrix Metalloproteinase 2; Perfusion; Portal Vein; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2023 |
Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues.
Topics: Cell Cycle; Cell Proliferation; Connective Tissue; Fibroblasts; Fibrosis; Humans | 2023 |
Another piece in the pirfenidone puzzle.
Topics: Fibrosis; Humans; Pyridones | 2023 |
A fibroblastic foci-targeting and hypoxia-cleavable delivery system of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Topics: Animals; Fibroblasts; Fibrosis; Idiopathic Pulmonary Fibrosis; Lung; Mice | 2023 |
Inhibition of TGF-β2-Induced Trabecular Meshwork Fibrosis by Pirfenidone.
Topics: Actins; Animals; Cells, Cultured; Fibrosis; Glaucoma; Glaucoma, Open-Angle; Humans; Mice; Ocular Hypertension; Ophthalmic Solutions; Trabecular Meshwork; Transforming Growth Factor beta2 | 2023 |
Pirfenidone attenuates the profibrotic contractile phenotype of differentiated human dermal myofibroblasts.
Topics: Adult; Cell Differentiation; Cells, Cultured; Cicatrix, Hypertrophic; Extracellular Matrix; Fibrosis; Humans; Myofibroblasts; Pyridones; Skin; Transforming Growth Factor beta1 | 2020 |
The
Topics: Cell Cycle Checkpoints; Cell Line; Cell Movement; Cell Proliferation; Fibroblasts; Fibrosis; Flow Cytometry; Gene Expression Regulation; Humans; Matrix Metalloproteinase 1; Pterygium; Pyridones; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Transforming Growth Factor beta2 | 2020 |
Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cells, Cultured; Cicatrix; Collagen; Drug Evaluation, Preclinical; Extracellular Matrix; Fibroblasts; Fibronectins; Fibrosis; Humans; Indoles; Protein Kinase Inhibitors; Pyridones; Transforming Growth Factor beta1 | 2020 |
Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fibrosis; Heart Diseases; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; PPAR alpha; Pyridones; Random Allocation | 2021 |
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell Proliferation; Cell Survival; Chemokine CCL2; Coculture Techniques; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Mast Cells; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridones; Rats; Recombinant Proteins; Signal Transduction; Stem Cell Factor; Vital Capacity | 2020 |
Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
Topics: Cell Proliferation; Fibroblasts; Fibrosis; Humans; Pyridones | 2020 |
Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis.
Topics: Animals; Apoptosis; Bleomycin; Capillaries; Dicarboxylic Acids; Endothelial Cells; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Mice; Mice, Inbred C57BL; Pyridones; Regeneration | 2020 |
Pirfenidone inhibits fibroblast proliferation, migration or adhesion and reduces epidural fibrosis in rats via the PI3K/AKT signaling pathway.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Epidural Space; Fibrosis; Humans; Laminectomy; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridones; Rats; Rats, Sprague-Dawley; Signal Transduction | 2021 |
Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro.
Topics: Animals; Anti-Inflammatory Agents; Fibrosis; Osteoarthritis; Pyridones; Rabbits; Synovial Membrane | 2021 |
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cell Differentiation; Collagen; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Gene Expression Profiling; Humans; Interleukin-10; Lectins, C-Type; Lymphocytes; Male; Mice; Middle Aged; Myofibroblasts; Pyridones; Receptors, Immunologic; Scleroderma, Systemic; Skin; Transforming Growth Factor beta | 2021 |
Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A.
Topics: Animals; Disease Models, Animal; Fibrosis; Inflammation; Interleukin-17; Janus Kinases; Lung; Mice; Mice, Inbred C57BL; Pneumonia; Pyridones; Signal Transduction; Silicon Dioxide; STAT Transcription Factors | 2022 |
Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-β1/Smad3 pathway.
Topics: Animals; Bone Marrow Cells; Female; Fibrosis; Lung Injury; Macrophage Activation; Mice; Mice, Inbred C57BL; Pyridones; RAW 264.7 Cells; Smad3 Protein; Transforming Growth Factor beta1 | 2021 |
Pirfenidone reduces subchondral bone loss and fibrosis after murine knee cartilage injury.
Topics: Animals; Bone and Bones; Cartilage, Articular; Fibrosis; Glycosaminoglycans; Hyaluronan Synthases; Hyaluronic Acid; Knee Injuries; Male; Mice; Mice, Inbred C57BL; Osteoarthritis, Knee; Pyridones | 2018 |
Test of Antifibrotic Drugs in a Cellular Model of Fibrosis Based on Muscle-Derived Fibroblasts from Duchenne Muscular Dystrophy Patients.
Topics: Cell Movement; Cell Proliferation; Collagen; Fibroblasts; Fibrosis; Humans; Muscles; Muscular Dystrophy, Duchenne; Primary Cell Culture; Pyridones | 2018 |
Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Bronchoalveolar Lavage Fluid; Fibrosis; Gene Expression; Gene Expression Profiling; Herbicides; Hydroxyproline; Lung; Lung Injury; Male; Mice; Organ Size; Oxidative Stress; Paraquat; Pneumonia; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1 | 2018 |
Pirfenidone prevents radiation-induced intestinal fibrosis in rats by inhibiting fibroblast proliferation and differentiation and suppressing the TGF-β1/Smad/CTGF signaling pathway.
Topics: Animals; Cell Differentiation; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Cytoprotection; Fibroblasts; Fibrosis; Intestines; Male; Pyridones; Radiation Injuries, Experimental; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2018 |
Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro.
Topics: Actins; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Fibrosis; Humans; MAP Kinase Signaling System; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; Pyridones; Skin; Transforming Growth Factor beta1 | 2018 |
Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Topics: Actins; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Culture Media, Conditioned; Drug Combinations; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Laminin; Phenotype; Phosphorylation; Primary Cell Culture; Proteoglycans; Pyridones; Signal Transduction; Smad3 Protein; STAT3 Transcription Factor; Transforming Growth Factor beta | 2018 |
Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Caspase 1; Cell Line; Fibrosis; Inflammasomes; Interleukin-1beta; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Pneumonia; Pyridones; Reactive Oxygen Species; Transforming Growth Factor beta1 | 2018 |
Fibrotic microtissue array to predict anti-fibrosis drug efficacy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Drug Evaluation, Preclinical; Fibroblasts; Fibrosis; Humans; Indoles; Lung; Lung Compliance; Primary Cell Culture; Pulmonary Fibrosis; Pyridones; Tissue Culture Techniques; Tissue Scaffolds; Treatment Outcome | 2018 |
Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen; Extracellular Matrix; Female; Fibroblasts; Fibrosis; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Pyridones; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Development of a biodegradable antifibrotic local drug delivery system for glaucoma microstents.
Topics: Animals; Caffeic Acids; Drug Delivery Systems; Drug-Eluting Stents; Fibrosis; Glaucoma; Male; Paclitaxel; Phenylethyl Alcohol; Pyridones; Rats; Rats, Wistar | 2018 |
Molecular characterization of a precision-cut rat lung slice model for the evaluation of antifibrotic drugs.
Topics: Animals; Biomarkers; Collagen Type I; Extracellular Matrix; Fibrosis; Indoles; Lung; Pyridones | 2019 |
Prevention of tracheal stenosis with pirfenidone after tracheotomy: An experimental study.
Topics: Animals; Fibrosis; Immunohistochemistry; Inflammation; Interleukin-1beta; Pyridones; Rats; Rats, Sprague-Dawley; Tracheal Stenosis; Tracheotomy; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2019 |
Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Topics: Aged; Animals; Antineoplastic Agents; Female; Fibrosis; Fluorodeoxyglucose F18; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Male; Mice; Mice, Inbred C57BL; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Pyridones | 2019 |
Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial.
Topics: Adult; Aged; Double-Blind Method; Female; Fibrosis; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pyridones; Stroke Volume; Ventricular Function, Left | 2019 |
The effect of an antifibrotic agent, pirfenidone, on penile erectile function in an experimental rat model of ischemic priapism.
Topics: Administration, Oral; Animals; Disease Models, Animal; Electric Stimulation; Fibrosis; Ischemia; Male; Photomicrography; Priapism; Pyridones; Random Allocation; Rats; Rats, Wistar | 2020 |
Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model.
Topics: Allografts; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Fibrosis; Graft Rejection; Kidney Transplantation; Kidney Tubules; Male; Protective Agents; Pyridones; Rats; Rats, Inbred F344; Rats, Inbred Lew; Renal Insufficiency, Chronic | 2019 |
Pirfenidone: a potential therapy for progressive lung allograft dysfunction?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Cell Proliferation; Disease Progression; Female; Fibrosis; Forced Expiratory Volume; Humans; Lung; Lung Transplantation; Middle Aged; Pyridones; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Collagen; Constriction; Fibrosis; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Interleukin-1beta; Male; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Myocytes, Cardiac; Myofibroblasts; NLR Family, Pyrin Domain-Containing 3 Protein; Pyridones; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Survival Rate; Transforming Growth Factor beta1; Ventricular Remodeling | 2013 |
Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Fibrosis; Humans; Kidney Tubules, Proximal; Male; Mitochondria; Nephrectomy; Nephritis, Interstitial; Pyridones; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic | 2013 |
Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Catalase; Fibrosis; Gene Expression Regulation; Hypertension, Renal; Kidney; Male; Matrix Metalloproteinase 9; Oxidative Stress; Proteinuria; Pyridones; Rats; Rats, Inbred Dahl; Signal Transduction; Smad2 Protein; Smad3 Protein; Sodium Chloride, Dietary; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2013 |
Pirfenidone prevents rat esophageal stricture formation.
Topics: Animals; Antineoplastic Agents; Connective Tissue Growth Factor; Drug Evaluation, Preclinical; Esophageal Stenosis; Esophagitis; Fibrosis; Gene Expression; Male; Plasminogen Activator Inhibitor 1; Pyridones; Rats, Wistar; Sodium Hydroxide; Transforming Growth Factor beta1; Wound Healing | 2015 |
Pirfenidone attenuates bladder fibrosis and mitigates deterioration of bladder function in a rat model of partial bladder outlet obstruction.
Topics: Animals; Disease Models, Animal; Fibrosis; Male; Pyridones; Rats, Sprague-Dawley; Urinary Bladder; Urinary Bladder Neck Obstruction | 2015 |
Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts.
Topics: Animals; Capillary Permeability; Cardiotonic Agents; Cells, Cultured; Claudin-5; Collagen Type I; Endothelial Cells; Fibroblasts; Fibrosis; Heart Failure; Heart Ventricles; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; Pyridones | 2015 |
XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-β1-stimulated C3H10T1/2 cells via Smad2/4.
Topics: Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Fibrosis; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridones; Pyrimidinones; Smad2 Protein; Smad4 Protein; Structure-Activity Relationship; Transforming Growth Factor beta1 | 2015 |
Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients.
Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Child, Preschool; Collagen; Fibroblasts; Fibrosis; Humans; Muscles; Muscular Dystrophy, Duchenne; Pyridones | 2016 |
Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cell Proliferation; Collagen; Disease Models, Animal; Female; Fibrosis; Immunoenzyme Techniques; Intestinal Diseases; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Transforming Growth Factor beta | 2016 |
Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation.
Topics: Animals; Cicatrix; Disease Models, Animal; Fibrosis; Foreign-Body Reaction; Glaucoma Drainage Implants; Pyridones; Rabbits; Wound Healing | 2016 |
Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn's disease.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Cells, Cultured; Collagen; Crohn Disease; Denmark; Endoscopy; Female; Fibroblasts; Fibrosis; Humans; Intestinal Mucosa; Linear Models; Male; Matrix Metalloproteinase 3; Pyridones; Tissue Inhibitor of Metalloproteinase-1 | 2016 |
Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.
Topics: Actins; Animals; Antigens, CD; Cadherins; Cell Line; Collagen Type I; Collagen Type III; Disease Models, Animal; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Fibronectins; Fibrosis; Humans; JNK Mitogen-Activated Protein Kinases; Kidney Diseases; Kidney Tubules, Proximal; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridones; Rats, Sprague-Dawley; Renal Agents; S100 Calcium-Binding Protein A4; Transforming Growth Factor beta1; Ureteral Obstruction | 2017 |
Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia.
Topics: Acetylcysteine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disulfiram; Fibrosis; Guinea Pigs; Humans; Pancreas; Pancreatic Neoplasms; Pancreatic Stellate Cells; Pyridones; Rats; Xenograft Model Antitumor Assays | 2016 |
Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model.
Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Proliferation; Cell Survival; Colitis; Collagen; Colon; Disease Models, Animal; Female; Fibrosis; Gastrointestinal Agents; Humans; Intestinal Mucosa; Mice, Inbred C57BL; Pyridones; Random Allocation; Signal Transduction; Specific Pathogen-Free Organisms; Transforming Growth Factor beta | 2016 |
Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis.
Topics: Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Collagen Type III; Feedback, Physiological; Fibrosis; Hemodynamics; Hydroxyproline; Liver X Receptors; Male; Myocardial Infarction; Myocardium; p38 Mitogen-Activated Protein Kinases; Peptidyl-Dipeptidase A; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyridones; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Signal Transduction; Systole; Ventricular Dysfunction | 2017 |
Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Cells, Cultured; Extracellular Matrix; Fibroblasts; Fibronectins; Fibrosis; Gene Expression Regulation; Humans; Pyridones; Signal Transduction; Transforming Growth Factor beta | 2017 |
A role of pancreatic stellate cells in islet fibrosis and β-cell dysfunction in type 2 diabetes mellitus.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Diabetes Mellitus, Type 2; Fibrosis; Humans; Insulin-Secreting Cells; Male; Pancreas; Pancreatic Stellate Cells; Pyridones; Rats, Inbred OLETF; Rats, Sprague-Dawley | 2017 |
Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells.
Topics: Animals; Cells, Cultured; Collagen Type I; Fibrosis; Kidney; Kidney Tubules, Proximal; NADPH Oxidases; Pyridones; Rats; Superoxides; Transforming Growth Factor beta1 | 2009 |
Renoprotective properties of pirfenidone in subtotally nephrectomized rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Differentiation; Cell Line; Chronic Disease; Disease Progression; Enalapril; Epithelial Cells; Fibrosis; Kidney; Kidney Failure, Chronic; Male; Mesoderm; Nephrectomy; Proteinuria; Pyridones; Rats; Rats, Wistar; Transforming Growth Factor beta | 2010 |
Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias.
Topics: Animals; Echocardiography; Electrophysiologic Techniques, Cardiac; Fibrosis; Heart Conduction System; Heart Ventricles; Male; Myocardial Infarction; Neural Conduction; Pyridones; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Ventricular Function, Left; Ventricular Remodeling; Voltage-Sensitive Dye Imaging | 2010 |
Scarred by disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cicatrix; Collagen; Fibrosis; Humans; Pyridones; Skin; United States; United States Food and Drug Administration | 2011 |
The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Cardiomegaly; Fibrosis; Heart; Heart Rate; Hypertension; Male; Mice; Mice, Inbred BALB C; Myocardium; Pyridones | 2012 |
Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones.
Topics: Animals; Cell Proliferation; Drug Design; Fibrosis; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Mice; Monosaccharides; NIH 3T3 Cells; Pyridones; Solubility | 2012 |
Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cell Line; Cell Movement; Collagen; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fibronectins; Fibrosis; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; Protein Transport; Pyridones; Retinal Pigment Epithelium; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1; Vitreoretinopathy, Proliferative | 2012 |
Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells.
Topics: Animals; Cells, Cultured; Epithelial Cells; Fibrosis; Kidney Tubules, Proximal; Pyridones; Rats; RNA, Messenger; Transforming Growth Factor beta1; Urothelium | 2012 |
Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Platelet-Derived Growth Factor; Pyridones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured | 2013 |
Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Fibrosis; Half-Life; Injections, Intravenous; Male; Mice; Pyridones; Spectrum Analysis; Tissue Distribution | 2002 |
Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Drug Interactions; Fibrosis; Kidney Diseases; Male; Pyridones; Rats; Rats, Sprague-Dawley; Vanadates | 2002 |
Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Cytokines; Cytotoxicity Tests, Immunologic; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Graft Rejection; Immunosuppressive Agents; Pyridones; Rats; Rats, Inbred Lew; Staining and Labeling; Trachea | 2002 |
Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis; Kidney; Kidney Diseases; Male; Mice; Proteinuria; Pyridones; Sclerosis; Time Factors | 2003 |
The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Collagen Type III; Collagenases; Fibrosis; Gene Expression Regulation, Enzymologic; Immunosuppressive Agents; Kidney Diseases; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrolimus; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta | 2005 |
Long-term administration of pirfenidone improves cardiac function in mdx mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiomyopathies; Disease Models, Animal; Fibrosis; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Myocardium; Pyridones; RNA, Messenger; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2006 |
A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Collagen; Disease Models, Animal; Fibrosis; In Vitro Techniques; Isometric Contraction; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1 | 2007 |
Do we have a pill for renal fibrosis?
Topics: Chronic Disease; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones; Tablets | 2007 |
Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Chlorhexidine; Fibrosis; Intestines; Liver; Male; Peritonitis; Pyridones; Rats; Rats, Wistar; Sclerosis | 1995 |
Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Northern; Body Weight; Collagen; Creatinine; Fibrosis; Hydroxyproline; Kidney; Male; Nephrectomy; Pyridones; Rats; Rats, Wistar; RNA, Messenger; Transforming Growth Factor beta | 1997 |
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Collagen; Disease Models, Animal; Fibrosis; Gelatinases; Hydroxyproline; Inulin; Kidney Cortex; Kidney Function Tests; Ligation; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; RNA, Ribosomal, 18S; RNA, Ribosomal, 28S; Transforming Growth Factor beta; Ureter; Ureteral Obstruction | 1998 |
Chronic progressive interstitial fibrosis in renal disease--are there novel pharmacological approaches?
Topics: Animals; Chronic Disease; Extracellular Matrix Proteins; Fibrosis; Humans; Kidney; Pyridones; Renin-Angiotensin System; Tumor Necrosis Factor-alpha | 1999 |
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calcium Chloride; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drinking; Eating; Fibrosis; Glomerular Filtration Rate; Heart Ventricles; In Vitro Techniques; Kidney; Male; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Norepinephrine; Pyridones; Quinolines; Rats; Rats, Wistar; Spironolactone; Thiadiazines; Vasoconstriction; Vasoconstrictor Agents | 2001 |
Retinoic acid exacerbates experimental radiation nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Extracellular Matrix; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Kidney Failure, Chronic; Proteinuria; Pyridones; Radiation Injuries, Experimental; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidines; Tretinoin; Uremia; Whole-Body Irradiation | 2002 |
Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.
Topics: Amiloride; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Biological Availability; Collagen; Desoxycorticosterone; Fibrosis; Hypertension; Hypertrophy, Left Ventricular; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Myocardium; Norepinephrine; Pyridones; Rats; Rats, Wistar; Sodium Chloride, Dietary; Vasoconstrictor Agents | 2002 |